Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-03-03 10:06 am Sale |
2023-02-24 | 13D | CinCor Pharma, Inc. CINC |
Sofinnova Capital IX | 0 0.000% |
-4,220,979 (Position Closed) |
Filing History |
| 2023-03-01 1:38 pm Sale |
2023-02-24 | 13D | CinCor Pharma, Inc. CINC |
Sofinnova Venture Partners X L.P. | 0 0.000% |
-6,109,360 (Position Closed) |
Filing History |
| 2023-02-28 4:30 pm Sale |
2023-02-24 | 13D | CinCor Pharma, Inc. CINC |
5AM Ventures VI L.P. | 0 0.000% |
-4,937,646 (Position Closed) |
Filing History |
| 2023-02-28 4:16 pm Sale |
2023-02-24 | 13D | CinCor Pharma, Inc. CINC |
GENERAL ATLANTIC PARTNERS LLC | 0 0.000% |
-4,209,470 (Position Closed) |
Filing History |
| 2023-02-14 2:30 pm Purchase |
2022-12-31 | 13G | CinCor Pharma, Inc. CINC |
PERCEPTIVE ADVISORS LLC | 2,576,325 5.900% |
2,576,325 (New Position) |
Filing History |
| 2023-02-13 1:33 pm Purchase |
2023-02-10 | 13D | CinCor Pharma, Inc. CINC |
Sofinnova Capital IX | 4,220,979 9.600% |
4,220,979 (New Position) |
Filing History |
| 2023-02-09 08:33 am Purchase |
2022-12-31 | 13G | CinCor Pharma, Inc. CINC |
ADAGE CAPITAL PARTNERS GP LLC | 2,993,182 6.840% |
852,636 (+39.83%) |
Filing History |
| 2023-01-18 4:00 pm Purchase |
2023-01-08 | 13D | CinCor Pharma, Inc. CINC |
5AM Ventures VI L.P. | 4,937,646 11.300% |
600,000 (+13.83%) |
Filing History |
| 2023-01-11 3:01 pm Purchase |
2023-01-09 | 13D | CinCor Pharma, Inc. CINC |
GENERAL ATLANTIC PARTNERS LLC | 4,209,470 9.600% |
83,000 (+2.01%) |
Filing History |
| 2022-09-26 4:18 pm Sale |
2022-01-11 | 13G | CinCor Pharma, Inc. CINC |
venBio Global Strategic Fund III L.P. | 1,862,256 4.900% |
-118,450 (-5.98%) |
Filing History |
| 2022-08-19 5:38 pm Purchase |
2022-08-11 | 13D | CinCor Pharma, Inc. CINC |
Sofinnova Venture Partners X L.P. | 6,109,360 14.300% |
535,411 (+9.61%) |
Filing History |
| 2022-01-21 4:47 pm Purchase |
2022-01-11 | 13G | CinCor Pharma, Inc. CINC |
ADAGE CAPITAL PARTNERS GP LLC | 2,140,546 5.860% |
2,140,546 (New Position) |
Filing History |
| 2022-01-21 4:15 pm Purchase |
2022-01-11 | 13G | CinCor Pharma, Inc. CINC |
5AM Ventures VI L.P. | 4,337,646 11.900% |
4,337,646 (New Position) |
Filing History |
| 2022-01-21 3:19 pm Purchase |
2022-01-11 | 13D | CinCor Pharma, Inc. CINC |
Sofinnova Venture Partners X L.P. | 5,573,949 15.300% |
5,573,949 (New Position) |
Filing History |
| 2022-01-21 1:07 pm Purchase |
2022-01-11 | 13D | CinCor Pharma, Inc. CINC |
GENERAL ATLANTIC PARTNERS LLC | 4,126,470 11.300% |
4,126,470 (New Position) |
Filing History |
| 2022-01-11 4:46 pm Purchase |
2022-01-11 | 13G | CinCor Pharma, Inc. CINC |
venBio Global Strategic Fund III L.P. | 1,980,706 5.600% |
1,980,706 (New Position) |
Filing History |
| 2022-01-11 4:05 pm Purchase |
2022-01-06 | 13G | CinCor Pharma, Inc. CINC |
CinRx Pharma LLC | 3,630,102 7.800% |
3,630,102 (New Position) |
Filing History |